FREE Account Opening + No Clearing Fees

Chemcon Speciality Chem IPO review (Apply)

Review By Dilip Davda on September 19, 2020

•    CSCL is a mega player in HMDS, CMIC speciality chemicals.
•    It is gearing for 67% capacity expansion, to be operational by Q1 of CY2022.
•    Its revenue from exports has posted CAGR of 17.57% in last three fiscals.
•    The company enjoys a good long term relationship with major clients.
•    Speciality chemical segment is witnessing preference of investors at large.

CSCL is gearing to take advantage of current India-China trade issue.  It was importing nearly 75% of its raw material from China, but ever since China-India issue crop up, it has already opened alternate sources of its raw materials from other neighbouring countries. The company is in the process of expanding its capacities by 67% and new two plants will be operational by the first quarter of CY2022. With virtual monopoly in its product line, it enjoys a higher margin per KG (kilogram) basis and thus stays insulated against the volatility of raw material as well as final product pricing.

Chemcon Speciality Chemicals Ltd.  (CSCL) is a manufacturer of specialized chemicals, such as HMDS and CMIC which are predominantly used in the pharmaceuticals industry (the 'Pharmaceutical Chemicals'), and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry (the 'Oil well Completion Chemicals'). CSCL  claims that it is the only manufacturer of HMDS in India and is the third-largest manufacturer of HMDS worldwide in terms of production in the calendar year 2019 (source: Frost & Sullivan Report). The company is the largest manufacturer of CMIC in India and the second-largest manufacturer of CMIC worldwide, in terms of production and capacity in the calendar year 2019 (source: Frost & Sullivan Report). Further, CSCL is the only manufacturer of Zinc Bromide and the largest manufacturer of Calcium Bromide in India, in terms of production in the calendar year 2019 (source: Frost & Sullivan Report).

The company supplies products to domestic customers and also export to countries including United States of America, Italy, South Korea, Germany, People's Republic of China, Japan, United Arab Emirates, Serbia, Russia, Spain, Thailand and Malaysia. In Fiscals 2020, 2019 and 2018, its revenue from exports (including Deemed Exports) contributed 39.78%, 31.99% and 47.84%, respectively of its revenue from operations.

CSCL's revenues from exports (including Deemed Exports) have grown at a CAGR of 17.57% between Fiscals 2018 and 2020. The key customers of its Pharmaceutical Chemicals include Hetero Labs Limited, Laurus Labs Limited, Aurobindo Pharma Limited, Sanjay Chemicals (India) Private Limited, Lantech Pharmaceuticals Limited, Ind -Swift Laboratories Limited, Vivin Drugs & Pharmaceuticals Limited and Macleods Pharmaceuticals Limited and the key customers of Oilwell Completion Chemicals include Shree Radha Overseas, Water Systems Specialty Chemical DMCC and CC Gran Limited Liability Company.

CSCL is an ISO 9001:2015 and ISO 14001:2015 certified company for the 'Manufacture and supply of pharmaceutical intermediates, silanes and oilfield chemicals'. Its manufacturing facility is located at Manjusar near Vadodara in Gujarat. As on the date of the Red Herring Prospectus, within its Manufacturing Facility, it currently has seven operational plants of which two plants are dedicated to the manufacturing of HMDS and ancillary products (including one plant dedicated to the manufacturing of hi-purity HMDS), one multipurpose plant, currently being used for manufacturing of HMDS and other pharmaceutical chemicals, two plants are dedicated to the manufacturing of CMIC and two plants dedicated to the manufacturing of Oilwell Completion Chemicals, along with three warehouses for the storage of products and raw materials. The company also has an in-house laboratory at its Manufacturing Facility to test raw materials procured, as well as products at the various stages of the manufacturing process. Further, it has five leased warehouses located outside Manufacturing Facility, in Manjusar, Vadodara.


To part finance its plans of capital expenditure for expansion of capacities (Rs. 41.03 cr.), working capital (Rs. 90.00 cr.), general corpus fund etc., CSCL is coming out with a maiden IPO with a combo offer of fresh equity issue (Rs. 165 cr.) and offer for sale (Rs. 153 cr.). It consists fresh equity issue of approx 4852941 shares of Rs. 10 each and offer for sale of 4500000 shares. The issue opens for subscription on September 21, 2020, and will close on September 23, 2020. The company has fixed the price band of Rs. 338 - Rs. 340 per share. Minimum application is to be made for 44 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE and NSE. CSCL mulls mobilizing around Rs. 318 cr. (based on upper price band) through this IPO. Issue constitutes 25.53% of the post issue paid-up capital of the company.

Having issued/converted entire equity at par, the company also issued bonus shares in the ratio of 3 for 1 in November 2018.

The average cost of acquisition of shares by the promoters/ selling stakeholders is Rs. 0.33 and Rs. 0.57 per share. Post issue, CSCL's current paid-up equity capital of Rs. 31.78 cr. will stand enhanced to Rs. 36.63 cr. With this issue, the company is looking for a market cap of Rs. 1245.44 cr.

The issue is jointly lead managed by Intensive Fiscal Services Pvt. Ltd. and Ambit Capital Pvt. Ltd., while Link Intime India Pvt. Ltd. is the registrar to the issue.

On the financial performance front, on a consolidated basis, CSCL has posted turnover/net profits of Rs. 158.39 cr. / Rs. 26.38 cr. (FY18), Rs. 305.33 cr. / Rs. 43.04 cr. (FY19) and Rs. 266.02 cr. / Rs. 48.85 cr. (FY20). For the last three fiscals, CSCL has posted CAGR of 29 % in revenue and 36% in PAT.

For the last three fiscals, on a consolidated basis, CSCL has posted an average EPS of Rs. 13.59 and an average RoNW of 40.30%. The issue is priced at a P/BV of 7.57 based on its NAV of Rs. 44.91 as on March 31, 2020, and at a P/BV of 4.05 based on post issue NAV of Rs. 84 (based on upper price band).

If we attribute latest earnings on fully diluted equity post issue, then asking price is at a P/E of around 25.49 against peer group P/E of 31.30. Thus prima facie issue is reasonably priced.

The two Book Running Lead Managers associated with this issue have not handled public issues in the past three years.  

As per offer documents, CSCL has shown Aarti Ind., Vinati Organics, Sudarshan Chemicals, Atul Ltd., Paushak Ltd., Fine Organics and Neogen Chemicals as its listed peers. Currently, they are trading at a P/Es of around 39.75, 42.48, 27.94, 31.26, 39.14, 55.64 and 55.59 (as on September 18, 2020 closing). However, they are strictly not comparable on an apple to apple basis.

Conclusion / Investment Strategy

CSCL has posted steady growth in its bottom line despite all odds. It is adding new capacities of 67% which will be operations by the first quarter of CY2022. Many of its products have lion market share. Issue pricing appears reasonable. Investors may consider investment for the medium to long term.

Reviewer recommends Subscribing to the issue.

Review By Dilip Davda on September 19, 2020

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Chemcon IPO FAQs

  1. 1. Why Chemcon IPO?

    The initial public offer (IPO) of Chemcon Speciality Chemicals Limited offers an early investment opportunity in Chemcon Speciality Chemicals Limited. A stock market investor can buy Chemcon IPO shares by applying in IPO before Chemcon Speciality Chemicals Limited shares get listed at the stock exchanges. An investor could invest in Chemcon IPO for short term listing gain or a long term.

  2. 3. Chemcon IPO what should investors do?

    Chemcon IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Chemcon IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  3. 4. Is Chemcon IPO good?

    Our recommendation for Chemcon IPO is to subscribe.

  4. 5. Is Chemcon IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe to the Chemcon IPO.

  5. 6. When will Chemcon IPO allotment status?

    The Chemcon IPO allotment status will be available on or around September 28, 2020. The allotted shares will be credited in demat account by September 30, 2020. Visit Chemcon IPO allotment status to check.

  6. 7. When will Chemcon IPO list?

    The Chemcon IPO will list on Thursday, October 1, 2020, at BSE, NSE.
More Chemcon IPO Views / Analysis / Recommendations ...


2. VATSAL RANA     Link|September 29, 2020 8:03:12 AM
1. Kuldeep Vaishnav     Link|September 23, 2020 3:01:18 PM
Can any body help me to understand about message showing as application under process while applying in IPO. neither amount is block nor deducted. will the application be processed ?